In animal models, spermidine demonstrably and causally plays a central role in autophagy and lifespan extension. In humans there are promising epidemiological signals, but controlled clinical trials testing supplements in humans are still lacking. Caution is warranted when translating animal experiments into supplement recommendations.
Spermidine is a naturally occurring substance (a so-called polyamine) that the body produces on its own and that also enters the body through food, for example via wheat germ, cheese, mushrooms and legumes. As we age, spermidine concentrations in the blood and tissues decline measurably. Whether that decline is a cause or a consequence of ageing has not yet been established (PMID 30306826).
In laboratory animals such as yeast, worms, fruit flies and mice, the evidence is strong and causal: spermidine is necessary for the cellular clean-up process known as autophagy. Autophagy is a kind of internal waste-collection service in which damaged proteins and cellular components are broken down and recycled. When researchers genetically disable spermidine production, the lifespan-extending effects of fasting disappear entirely. The same applies to rapamycin, a substance long known to extend lifespan in animal models: that compound also turns out to work by raising endogenous spermidine levels (PMID 39117797, 39212197). This makes spermidine a central pivot point in multiple anti-ageing pathways.
Cardiac protection and the reduction of joint inflammation (arthritis) through fasting also appear to depend on sufficient spermidine production in animal models. Block that production and the protective effects vanish (PMID 39117797). In aged mice and flies, additional dietary spermidine furthermore improves memory and learning ability, presumably because mitochondria (the energy powerhouses of the cell) function better and autophagy in brain cells increases (PMID 33852843). In a prospective human cohort, higher dietary spermidine intake was associated with a lower risk of cognitive decline, but controlled clinical trials in humans have not yet been conducted here.
Large-scale population research shows that people who consume large amounts of spermidine through their diet less frequently die from cardiovascular disease and cancer. These findings represent a statistical association, however, not proof that spermidine supplements produce the same effect. People who eat large amounts of spermidine-rich foods may also lead healthier lives in other respects (PMID 30306826).
The mechanism of action is not yet fully understood. In flies it has been shown that an enzyme called GNMT is required for spermidine to exert its autophagy-activating effect; without this enzyme, the lifespan extension also disappears. This mechanism has so far only been established in fly models (PMID 37004845).
In humans, spermidine is recognised as one of the promising candidates in ongoing anti-ageing research, but large-scale randomised clinical trials are still absent or still underway. Definitive evidence that spermidine supplements genuinely slow ageing in humans does not currently exist (PMID 38181790). The safety of long-term supplementation in humans has not been investigated in the available claims.
Evidence is strong and causal in model organisms (yeast, worms, flies, mice); in humans it consists of epidemiological associations and prospective cohort studies. Randomised clinical trials in humans are absent or still ongoing. The total number of human participants across the studies used cannot be precisely derived from the abstracts; the cohort study (PMID 30306826) encompassed an Austrian population study with thousands of participants.